{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.5","upperLimit":"80.9","value":"67.4"},{"groupId":"OG001","lowerLimit":"23.5","upperLimit":"61.1","value":"41.4"},{"groupId":"OG002","lowerLimit":"22.2","upperLimit":"56.4","value":"38.2"},{"groupId":"OG003","lowerLimit":"4.4","upperLimit":"34.9","value":"15.4"},{"groupId":"OG004","lowerLimit":"1.1","upperLimit":"29.2","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"OHR included CHR, no evidence of leukemia (≤5% bone marrow blasts, no peripheral blood blasts or promyelocytes, \\<5% myelocytes + metamyelocytes in blood, white blood cells ≤ institutional upper limit of normal, 450x10\\^9/L \\> platelets \\> 20x10\\^9/L, absolute neutrophil count ≥0.5x10\\^9/L, \\<20% basophils in blood, no extramedullary involvement \\[including liver or spleen\\]), minor hematologic response (acute lymphoblastic leukemia \\[ALL\\] patients only, defined as \\<15% blasts in marrow \\& blood, \\<30% blasts + promyelocytes in marrow \\& blood, \\<20% basophils in peripheral blood \\& no extramedullary disease other than spleen \\& liver) or return to chronic phase (AP/BP participants, defined as \\<15% blasts in both peripheral blood \\&bone marrow, \\<30% blasts + promyelocytes in both peripheral blood \\& bone marrow, \\<20% basophils in both peripheral blood \\& bone marrow, no extramedullary Involvement other than liver or spleen). Participants had to meet at least 1 criterion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG001","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG002","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG003","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG004","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"Hematologic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline hematologic assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 1 year","title":"Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}